about
sameAs
Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanismMitochondrial dysfunction in obesity: potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndromeAssociation between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysisStatin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementPolymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicityStatin intolerance - a question of definition.SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactomeSafety of statins: an updateEffects of statins on skeletal muscle: a perspective for physical therapists.Statin drug interactions and related adverse reactions.Mechanisms and assessment of statin-related muscular adverse effects.Mechanisms of statin-induced myalgia assessed by physiogenomic associations.Reversible dysphasia and statins.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsTreatment Options for Statin-Associated Muscle Symptoms.Prevalence of musculoskeletal pain and statin use.Coenzyme Q10: is there a clinical role and a case for measurement?High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Pharmacogenetics: potential role in the treatment of diabetes and obesityMood, Personality, and Behavior Changes During Treatment with Statins: A Case SeriesClinical characterization and molecular mechanisms of statin myopathy.Molecular basis for statin-induced muscle toxicity: implications and possibilities.Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy.Update on toxic myopathies.Towards companion diagnostics for the management of statin therapy.Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.Pharmacogenomics, lipid disorders, and treatment options.The role of mitochondria in statin-induced myopathy.Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challengePharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?Italian multicenter study on low-density lipoprotein apheresis Working Group 2009 survey.Point-Counterpoint: SLCO1B1 Genotyping for Statins.The Combination of Physical Exercise with Muscle-Directed Antioxidants to Counteract Sarcopenia: A Biomedical Rationale for Pleiotropic Treatment with Creatine and Coenzyme Q10.Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.Drug-Induced Mitochondrial Toxicity.Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?Pharmacogenetics of Adverse Drug Reactions
P2860
Q24603957-EA86BA97-EFB3-4344-8E95-1D1A24C901BBQ27009336-9FC1900B-4E16-4107-AA1E-6179E457376EQ28070052-46AC60D4-4E42-40B2-8275-499D0DFD039DQ28083004-A3BCA7DE-E45D-4EA5-94D9-A55741AFAA44Q28480419-316C0EDD-1E30-422D-A752-B5314060D02FQ30245218-6D4093BC-7534-4C34-8908-E4047FBA5FE1Q30488528-42557537-8C42-418B-A86B-241F71A70B42Q33949312-331E3A0B-7417-4D92-B4AD-9CDFEDEEEF47Q34173180-770E7FF6-6A11-4768-84B3-F17D95834F8BQ34292468-2AD93E29-790A-432C-B14F-212C64BD1EA5Q34570995-228E7404-D5E1-4B7C-9F1D-18193EEE8407Q35575560-76405EA2-E436-48D3-9AEE-6714FCDA494BQ35859277-EB9E910A-5E11-4CA2-81CD-2E30AB452F52Q35915932-E8CB8655-F86E-4526-BD60-A902613D0DC7Q36294394-B9AFA95C-57EA-49EB-9CA5-43E5F01EBF21Q36841011-D467EA1A-20D0-4EED-B463-806216568321Q36869671-AF4CBC13-AA92-43FB-8588-3FF192745CCEQ36979363-274C8ABB-4390-4801-A98C-D87AFFA4B254Q36986507-9C5A9E31-3174-45A9-BE18-F7BF948D909BQ37142047-3F75E991-A756-40D6-ACEE-F61C8EADE46AQ37218787-3DE128CA-56F4-41EE-AFD4-2C0869B07D3CQ37230383-2F772950-63EF-44F6-84B3-3D357899BB4CQ37235648-14ED2868-207E-4AA9-8371-D772CB9369E2Q37812387-0FFDEA95-96EF-48A5-A52A-8DE8F1A925B1Q37942033-8F49070D-4F67-49F2-B8E2-A1AE4B0EEC3BQ38089842-51A87AD1-C8C2-407B-869C-4ECEED44AB64Q38092053-DE6BECD7-71D7-49A0-AFDB-151C75853D25Q38203774-64AEDC64-A9ED-446F-8222-03DDAA9BF294Q38492567-4E51F564-1615-43E1-A7AF-28790931E0ACQ38644316-BC01A0B0-8443-444D-B1A8-AD84A6457240Q38780996-97A4F9C8-7B95-4A5D-A0AD-F7E0B81C18E7Q39229652-FF490011-3D5A-4CDC-9403-174BD1CA9A85Q41975807-254EC404-F80C-4902-BB54-7A8AA938C260Q45833603-6CF13442-FAD1-4BFE-AC08-F4423E0A857EQ47750262-9F05C1D7-B1F9-4A94-A889-4505C8C359B0Q51538858-3F8E6C3D-3199-4EB5-BBFD-29280B4DE403Q52600967-349473C1-FEFC-4E87-8DED-6394B0649D14Q57302676-2DDE4441-09C1-4788-9AAF-DA4EEAEA2B43
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Genetic determinants of statin intolerance
@ast
Genetic determinants of statin intolerance
@en
Genetic determinants of statin intolerance
@en-gb
Genetic determinants of statin intolerance
@nl
type
label
Genetic determinants of statin intolerance
@ast
Genetic determinants of statin intolerance
@en
Genetic determinants of statin intolerance
@en-gb
Genetic determinants of statin intolerance
@nl
prefLabel
Genetic determinants of statin intolerance
@ast
Genetic determinants of statin intolerance
@en
Genetic determinants of statin intolerance
@en-gb
Genetic determinants of statin intolerance
@nl
P2093
P2860
P3181
P356
P1476
Genetic determinants of statin intolerance
@en
P2093
Brooke A Miskie
Matthew R Ban
P2860
P2888
P3181
P356
10.1186/1476-511X-6-7
P407
P577
2007-01-01T00:00:00Z
P6179
1014748287